Literature DB >> 27696378

Probiotics, fibre and herbal medicinal products for functional and inflammatory bowel disorders.

Diego Currò1, Gianluca Ianiro2, Silvia Pecere2, Stefano Bibbò3, Giovanni Cammarota2.   

Abstract

Functional bowel disorders (FBD), mainly irritable bowel syndrome (IBS) and functional constipation (FC, also called chronic idiopathic constipation), are very common worldwide. Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, although less common, has a strong impact on patients' quality of life, as well as being highly expensive for our healthcare. A definite cure for those disorders is still yet to come. Over the years, several therapeutic approaches complementary or alternative to traditional pharmacological treatments, including probiotics, prebiotics, synbiotics, fibre and herbal medicinal products, have been investigated for the management of both groups of diseases. However, most available studies are biased by several drawbacks, including small samples and poor methodological quality. Probiotics, in particular Saccharomyces boulardii and Lactobacilli (among which Lactobacillus rhamnosus), synbiotics, psyllium, and some herbal medicinal products, primarily peppermint oil, seem to be effective in ameliorating IBS symptoms. Synbiotics and fibre seem to be beneficial in FC patients. The probiotic combination VSL#3 may be effective in inducing remission in patients with mild-to-moderate ulcerative colitis, in whom Escherichia coli Nissle 1917 seems to be as effective as mesalamine in maintaining remission. No definite conclusions can be drawn as to the efficacy of fibre and herbal medicinal products in IBD patients due to the low number of studies and the lack of randomized controlled trials that replicate the results obtained in the individual studies conducted so far. Thus, further, well-designed studies are needed to address the real role of these therapeutic options in the management of both FBD and IBD. LINKED ARTICLES: This article is part of a themed section on Principles of Pharmacological Research of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.11/issuetoc.
© 2016 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27696378      PMCID: PMC5429330          DOI: 10.1111/bph.13632

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  221 in total

1.  Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study.

Authors:  Alvah C Bittner; Robert M Croffut; Mary C Stranahan
Journal:  Clin Ther       Date:  2005-06       Impact factor: 3.393

2.  Binding of STW 5 (Iberogast) and its components to intestinal 5-HT, muscarinic M3, and opioid receptors.

Authors:  U Simmen; O Kelber; S N Okpanyi; R Jaeggi; B Bueter; D Weiser
Journal:  Phytomedicine       Date:  2006-09-14       Impact factor: 5.340

3.  Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification.

Authors:  Antonia Mattia; Robert Merker
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

4.  Inhibitory effects of Lactobacillus reuteri on visceral pain induced by colorectal distension in Sprague-Dawley rats.

Authors:  T Kamiya; L Wang; P Forsythe; G Goettsche; Y Mao; Y Wang; G Tougas; J Bienenstock
Journal:  Gut       Date:  2005-12-16       Impact factor: 23.059

Review 5.  Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases.

Authors:  J Langhorst; H Wulfert; R Lauche; P Klose; H Cramer; G J Dobos; J Korzenik
Journal:  J Crohns Colitis       Date:  2014-11-28       Impact factor: 9.071

6.  The effects of cardamonin on lipopolysaccharide-induced inflammatory protein production and MAP kinase and NFkappaB signalling pathways in monocytes/macrophages.

Authors:  S Hatziieremia; A I Gray; V A Ferro; A Paul; R Plevin
Journal:  Br J Pharmacol       Date:  2006-08-07       Impact factor: 8.739

7.  Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial.

Authors:  E Ben-Arye; E Goldin; D Wengrower; A Stamper; R Kohn; E Berry
Journal:  Scand J Gastroenterol       Date:  2002-04       Impact factor: 2.423

Review 8.  The effect of probiotics on functional constipation in adults: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Eirini Dimidi; Stephanos Christodoulides; Konstantinos C Fragkos; S Mark Scott; Kevin Whelan
Journal:  Am J Clin Nutr       Date:  2014-08-06       Impact factor: 7.045

9.  On the benefit of probiotics in the management of pouchitis in patients underwent ileal pouch anal anastomosis: a meta-analysis of controlled clinical trials.

Authors:  Behzad Elahi; Shekoufeh Nikfar; Saeed Derakhshani; Mohammad Vafaie; Mohammad Abdollahi
Journal:  Dig Dis Sci       Date:  2007-10-17       Impact factor: 3.199

10.  HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses.

Authors:  Kathrin S Michelsen; Michelle H Wong; Brian Ko; Lisa S Thomas; Deepti Dhall; Stephan R Targan
Journal:  Inflamm Bowel Dis       Date:  2013-01       Impact factor: 5.325

View more
  29 in total

1.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

Review 2.  Medicinal Foods for Functional GI Disorders.

Authors:  Brent W Acker; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2017-11-13

Review 3.  Design and implementation of novel nutraceuticals and derivatives for treating intestinal disorders.

Authors:  Maria J Barahona; Vanessa Baratta; Jenna Ollodart; David Mulligan; John P Geibel
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

Review 4.  Role of Short Chain Fatty Acids and Apolipoproteins in the Regulation of Eosinophilia-Associated Diseases.

Authors:  Eva Maria Sturm; Eva Knuplez; Gunther Marsche
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

5.  A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: results from a randomized double-blind placebo-controlled pilot trial.

Authors:  Iris Pinheiro; Larry Robinson; An Verhelst; Massimo Marzorati; Björn Winkens; Pieter Van den Abbeele; Sam Possemiers
Journal:  BMC Complement Altern Med       Date:  2017-09-04       Impact factor: 3.659

6.  Effect of Lactobacillus rhamnosus HN001 and Bifidobacterium longum BB536 on the healthy gut microbiota composition at phyla and species level: A preliminary study.

Authors:  Marco Toscano; Roberta De Grandi; Laura Stronati; Elena De Vecchi; Lorenzo Drago
Journal:  World J Gastroenterol       Date:  2017-04-21       Impact factor: 5.742

Review 7.  Are the Gut Bacteria Telling Us to Eat or Not to Eat? Reviewing the Role of Gut Microbiota in the Etiology, Disease Progression and Treatment of Eating Disorders.

Authors:  Yan Y Lam; Sarah Maguire; Talia Palacios; Ian D Caterson
Journal:  Nutrients       Date:  2017-06-14       Impact factor: 5.717

8.  Evaluation of Benefit and Tolerability of IQP-CL-101 (Xanthofen) in the Symptomatic Improvement of Irritable Bowel Syndrome: A Double-Blinded, Randomised, Placebo-Controlled Clinical Trial.

Authors:  Felix Alt; Pee-Win Chong; Emily Teng; Ralf Uebelhack
Journal:  Phytother Res       Date:  2017-05-16       Impact factor: 5.878

Review 9.  A Review of Microbiota and Irritable Bowel Syndrome: Future in Therapies.

Authors:  Bruno K Rodiño-Janeiro; María Vicario; Carmen Alonso-Cotoner; Roberto Pascua-García; Javier Santos
Journal:  Adv Ther       Date:  2018-03-01       Impact factor: 3.845

Review 10.  Vagus Nerve as Modulator of the Brain-Gut Axis in Psychiatric and Inflammatory Disorders.

Authors:  Sigrid Breit; Aleksandra Kupferberg; Gerhard Rogler; Gregor Hasler
Journal:  Front Psychiatry       Date:  2018-03-13       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.